iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022
April 08 2022 - 1:00PM
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of potentially differentiated immuno-oncology
therapeutics for patients, today announced a presentation featuring
preclinical and clinical analyses supporting the multifaceted
mechanism of action of its anti-TIGIT antibody,
EOS-448/GSK4428859A, which is being developed in collaboration with
GSK, at the American Association of Cancer Research (AACR) Annual
Meeting 2022, taking place April 8-13, 2022 in New Orleans,
Louisiana.
“We are excited to share new data in support of the multifaceted
mechanism of our high affinity, potent anti-TIGIT antibody,
EOS-448, that we believe support the important role of FcγR
engagement in strategies targeting TIGIT for the treatment of
cancer,” said Yvonne McGrath, Ph.D., chief scientific officer of
iTeos Therapeutics. “We’re also encouraged by the evidence of TIGIT
engagement in patient tumor biopsies, supporting our excitement for
EOS-448 as a potentially important advancement in immuno-oncology.
We look forward to continuing our assessment of EOS-448 in multiple
late-stage clinical trials with the goal of providing a more
effective treatment for people with advanced cancers.”
The presentation featured both preclinical and clinical evidence
for the multifaceted mechanism of action of EOS-448, including
activation of effector T cells, modulation of antigen-presenting
cells and depletion of immunosuppressive regulatory T cells (Tregs)
and terminally exhausted T cells which express TIGIT. Cell-based
assays demonstrate higher potency with EOS-448 compared to other
anti-TIGIT monoclonal antibodies in clinical development and
provided the basis for its selection as a therapeutic candidate.
Depletion of Tregs and exhausted CD8 T cells in patients with
advanced cancers who were treated with EOS-448 demonstrate target
engagement, providing additional evidence of potency.
Preclinical analyses of different anti-TIGIT antibody isotypes
in combination with an anti-PD1 antibody in a murine cancer model
demonstrate differences in anti-tumor activity depending on the
anti-TIGIT isotype tested. Only the FcγR-engaging isotype induces a
strong anti-tumor effect, which correlates with Treg depletion and
activation of effector CD8 T cells in the tumor microenvironment.
In addition, ex vivo analysis of human peripheral blood mononuclear
cells demonstrates that EOS-448 preferentially depletes Tregs and
progenitors of exhausted T cells, but not stem-like memory T cells.
Pharmacodynamic analyses in the blood of patients treated across
multiple dose levels of EOS-448 show sustained depletion of Tregs
and terminally exhausted CD8 T cells with high TIGIT expression,
resulting in an increased effector CD8 T cell/Treg ratio. In
patient tumor biopsies, treatment with EOS-448 results in a
decrease of TIGIT-expressing cells in the tumor; EOS-448 is the
first anti-TIGIT antibody to demonstrate target engagement in
patient tumors. These results are consistent with previously
reported data providing evidence of FcγR engagement with EOS-448
and demonstrating initial clinical activity for EOS-448 as a
monotherapy.
The abstract can be accessed on the AACR conference website. The
abstract details are as follows:
Title: Pharmacodynamic assessment of a-TIGIT
mAb EOS-448 highlights multiple FcγR-mediated mode-of-actions in
blood and tumor of patients with advanced solid tumors
Session Title: Late Breaking Research:
Experimental and Molecular Therapeutics 2Abstract
Number: LB189 / Section 16Authors: Julia
Cuende, et al.
About iTeos Therapeutics, Inc. iTeos
Therapeutics is a clinical-stage biopharmaceutical company
pioneering the discovery and development of a new generation of
highly differentiated immuno-oncology therapeutics for patients.
iTeos Therapeutics leverages its deep understanding of tumor
immunology and immunosuppressive pathways to design novel product
candidates with the potential to restore the immune response
against cancer. The Company’s innovative pipeline includes two
clinical-stage programs targeting novel, validated immuno-oncology
pathways designed with optimized pharmacologic properties with the
goal of improving clinical outcomes. The first antibody product
candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody
with a functional Fc domain, designed to enhance the anti-tumor
response through a multifaceted immune modulatory mechanism,
currently progressing in multiple indications in collaboration with
GSK. The Company is also advancing inupadenant, a next-generation
adenosine A2A receptor antagonist tailored to overcome cancer
immunosuppression into proof-of concept trials in several
indications following encouraging single-agent activity in Phase 1.
iTeos Therapeutics is headquartered in Watertown, MA with a
research center in Gosselies, Belgium.
Internet Posting of Information iTeos
routinely posts information that may be important to investors in
the 'Investors' section of its website at
www.iteostherapeutics.com. The Company encourages investors and
potential investors to consult our website regularly for important
information about iTeos.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995 and other federal
securities laws. Any statements that are not statements of
historical fact are forward-looking statements. Words such as
“believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,”
“prepare,” “look,” “potential,” “possible” and similar expressions
are intended to identify forward-looking statements.
Forward-looking statements include statements relating to the
potential benefits of our product candidates, including the
potential of EOS-448 to be an important advancement in
immuno-oncology; and our plans to continue our assessment of
EOS-448 in multiple late-stage clinical trials with the goal of
providing a more effective treatment for people with advanced
cancers.
These forward-looking statements involve risks and
uncertainties, many of which are beyond iTeos’ control. Actual
results could materially differ from those stated or implied by
these forward-looking statements as a result of such risks and
uncertainties. Known risk factors include the following: success in
preclinical testing and early clinical trials does not ensure that
later clinical trials will be successful, and early results from a
clinical trial do not necessarily predict final results; the data
for our product candidates may not be sufficient to support
regulatory approval; iTeos may not be able to execute on its
business plans, including meeting its expected or planned
regulatory milestones and timelines, research and clinical
development plans, and bringing its product candidates to market,
for various reasons, some of which may be outside of iTeos’
control, including possible limitations of company financial and
other resources, manufacturing limitations that may not be
anticipated or resolved for in a timely manner, regulatory, court
or agency decisions such as decisions by the United States Patent
and Trademark Office with respect to patents that cover our product
candidates and the impact of the COVID-19 pandemic; and those risks
identified under the heading “Risk Factors” in iTeos’ Annual Report
on Form 10-K for the year ended December 31, 2021 filed with the
Securities and Exchange Commission (SEC) as well as other SEC
filings made by the Company which you are encouraged to review.
Any of the foregoing risks could materially and adversely affect
iTeos’ business, results of operations and the trading price of
iTeos’ common stock. We caution investors not to place considerable
reliance on the forward-looking statements contained in this press
release. iTeos does not undertake any obligation to publicly update
its forward-looking statements based on events or circumstances
after the date hereof.
For further information, please contact:
Ryan BakerHead of Investor
RelationsiTeos Therapeutics321 Arsenal
StreetBldg 312, Suite 301Watertown,
MA 02472-5710Ryan.Baker@iteostherapeutics.com
Media Contact:media@iteostherapeutics.com
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Apr 2023 to Apr 2024